Comparison of magnetic resonance imaging of the prostate 1.5T and 3T
DOI:
https://doi.org/10.55378/rv.49.1.5Keywords:
MRI, prostate, 1.5T, 3TAbstract
With its excellent display of soft tissues and the possibilities of three-dimensional display, magnetic resonance has become one of the fundamental diagnostics in the display of prostate and its pathological conditions since its beginnings 40 years ago. Although there is greater availability of devices for magnetic resonance with a field strength of 1.5T, the recommendation of the European Association of Urogenital Radiologists is that imaging of the prostate with magnetic resonance is performed on devices with a field strength of 3T. 3T devices were introduced due to the increased signal-to-noise ratio (SNR), which can be used to shorten recording time or increase resolution, i.e. improve image quality. There is more and more research into the application of quantitative techniques such as Magnetic resonance fingerprinting, T2 mapping, BOLD, which could improve the detection and quantification of prostate cancer lesions, and by optimizing the protocol at 1.5T and 3T it is possible to perform exam of equal diagnostic value.
References
PI-RADS v2.1. (preuzeto 12.2.2023.) Dostupno na https://www.acr.org/-/media/ACR/Files/RADS/Pi-RADS/PIRADS-v2-1.pdf
Giganti F., Rosenkrantz B. A., Villeirs G., Panebianco V., Stabile A., Emberton M., Moore C. M. The Evolution of MRI of the Prostate: The Past, the Present, and the Future. AJR Am J Roentgenol. 2019 Aug; 213(2): 384-396.
Giganti F, Allen C. Imaging quality and prostate MR: it is time to improve. Br J Radiol. 2021 Feb 1;94(1118):20200934. doi: 10.1259/bjr.20200934.
Westbrook C., Talbot J. MRI in Practice, 5th Edition. Wiley-Blackwell, 2018.
Jambor I. Optimization of prostate MRI acquisition and post-processing protocol: a pictorial review with access to acquisition protocols. Acta Radiol Open. 2017 Dec 8;6(12):2058460117745574. doi: 10.1177/2058460117745574.
Maier SE, Wallström J, Langkilde F, Johansson J, Kuczera S, Hugosson J, Hellström M. Prostate Cancer Diffusion-Weighted Magnetic Resonance Imaging: Does the Choice of Diffusion-Weighting Level Matter? J Magn Reson Imaging. 2022 Mar;55(3):842-853. doi: 10.1002/jmri.27895.
Tamada T, Kido A, Ueda Y, Takeuchi M, Fukunaga T, Sone T, Yamamoto A. Clinical impact of ultra-high b-value (3000 s/mm2) diffusion-weighted magnetic resonance imaging in prostate cancer at 3T: comparison with b-value of 2000 s/mm2. Br J Radiol. 2022 Mar 1;95(1131):20210465. doi: 10.1259/bjr.20210465.
Polanec SH, Lazar M, Wengert GJ, Bickel H, Spick C, Susani M, Shariat S, Clauser P, Baltzer PAT. 3D T2-weighted imaging to shorten multiparametric prostate MRI protocols. Eur Radiol. 2018 Apr;28(4):1634-1641. doi: 10.1007/s00330-017-5120-5.
Vidya Shankar R, Roccia E, Cruz G, Neji R, Botnar R, Prezzi D, Goh V, Prieto C, Dregely I. Accelerated 3D T2 w-imaging of the prostate with 1-millimeter isotropic resolution in less than 3 minutes. Magn Reson Med. 2019 Aug;82(2):721-731. doi: 10.1002/mrm.27764.
Caglic I, Povalej Brzan P, Warren AY, Bratt O, Shah N, Barrett T. Defining the incremental value of 3D T2-weighted imaging in the assessment of prostate cancer extracapsular extension. Eur Radiol. 2019 Oct;29(10):5488-5497. doi: 10.1007/s00330-019-06070-6.
Alonzi R, Taylor NJ, Stirling JJ, d’Arcy JA, Collins DJ, Saunders MI, Hoskin PJ, Padhani AR. Reproducibility and correlation between quantitative and semiquantitative dynamic and intrinsic susceptibility-weighted MRI parameters in the benign and malignant human prostate. J Magn Reson Imaging. 2010 Jul;32(1):155-64. doi: 10.1002/jmri.22215.
Kim Y, Park JJ, Kim CK. Blood oxygenation level-dependent MRI at 3T for differentiating prostate cancer from benign tissue: a preliminary experience. Br J Radiol 2022; 95: 20210461.
Klingebiel M, Schimmöller L, Weiland E, Franiel T, Jannusch K, Kirchner J, Hilbert T, Strecker R, Arsov C, Wittsack HJ, Albers P, Antoch G, Ullrich T. Value of T2 Mapping MRI for Prostate Cancer Detection and Classification. J Magn Reson Imaging. 2022 Aug;56(2):413-422. doi: 10.1002/jmri.28061.
Mai J, Abubrig M, Lehmann T, Hilbert T, Weiland E, Grimm MO, Teichgräber U, Franiel T. T2 Mapping in Prostate Cancer. Invest Radiol. 2019 Mar;54(3):146-152. doi: 10.1097/RLI.0000000000000520.
Sathiadoss P, Schieda N, Haroon M, Osman H, Alrasheed S, Flood TA, Melkus G. Utility of Quantitative T2-Mapping Compared to Conventional and Advanced Diffusion Weighted Imaging Techniques for Multiparametric Prostate MRI in Men with Hip Prosthesis. J Magn Reson Imaging. 2022 Jan;55(1):265-274. doi: 10.1002/jmri.27803.
Al-Bourini O, Seif Amir Hosseini A, Giganti F, Balz J, Heitz LG, Voit D, Lotz J, Trojan L, Frahm J, Uhlig A, Uhlig J. T1 Mapping of the Prostate Using Single-Shot T1FLASH: A Clinical Feasibility Study to Optimize Prostate Cancer Assessment. Invest Radiol. 2022 Dec 8. doi: 10.1097/RLI.0000000000000945.
Sushentsev N, Kaggie JD, Slough RA, Carmo B, Barrett T. Reproducibility of magnetic resonance fingerprinting-based T1 mapping of the healthy prostate at 1.5 and 3.0 T: A proof-of-concept study. PLoS One. 2021 Jan 29;16(1):e0245970. doi: 10.1371/journal.pone. 0245970.
Shiradkar R, Panda A, Leo P, Janowczyk A, Farre X, Janaki N, Li L, Pahwa S, Mahran A, Buzzy C, Fu P, Elliott R, MacLennan G, Ponsky L, Gulani V, Madabhushi A. T1 and T2 MR fingerprinting measurements of prostate cancer and prostatitis correlate with deep learning-derived estimates of epithelium, lumen, and stromal composition on corresponding whole mount histopathology. Eur Radiol. 2021 Mar;31(3):1336-1346. doi: 10.1007/s00330-020-07214-9..
Tamada T, Kido A, Yamamoto A, Takeuchi M, Miyaji Y, Moriya T, Sone T. Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1. J Magn Reson Imaging. 2021 Jan;53(1):283-291. doi: 10.1002/jmri.27283.
Felisi M, Monti AF, Lizio D, Nici S, Pellegrini RG, Riga S, Bortolato B, Brambilla MG, Carbonini C, Abujami M, Carsana C, Sibio D, Potente C, Vanzulli A, Palazzi MF, Torresin A. MRI only in a patient with prostate cancer with bilateral metal hip prostheses: case study. Tumori. 2021 Dec;107(6):NP41-NP44. doi: 10.1177/0300891621997549.
Ullrich T, Quentin M, Oelers C, Dietzel F, Sawicki LM, Arsov C, Rabenalt R, Albers P, Antoch G, Blondin D, Wittsack HJ, Schimmöller L. Magnetic resonance imaging of the prostate at 1.5 versus 3.0T: A prospective comparison study of image quality. Eur J Radiol. 2017 May;90:192-197.
Virarkar M, Szklaruk J, Diab R, Bassett R, Bhosale P. Diagnostic value of 3.0 T versus 1.5 T MRI in staging prostate cancer: systematic review and meta-analysis. Pol J Radiol. 2022 Jul 29;87:e421-e429.
Kutlić G. Usporedba oslikavanja prostate magnetskom rezonancijom 1.5 T i 3 T (Diplomski rad). Split: Sveučilište u Splitu, Sveučilišni odjel zdravstvenih studija; 2023 (pristupljeno13.01.2025.) Dostupno na: https://urn.nsk.hr/urn:nbn:hr:176:919786
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2025 Goran Kutlić, Krešimir Dolić (Autor)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
CART